Patient Characteristics and Survival Outcomes of Non-Metastatic, Non-Clear Cell Renal Cell Carcinoma

Josiah An; Vignesh T. Packiam; Adithya Chennamadhavuni; Jordan Richards; Jayanshu Jain; Sarah L. Mott; Rohan Garje

doi:10.3389/fonc.2021.786307

Back

Patient Characteristics and Survival Outcomes of Non-Metastatic, Non-Clear Cell Renal Cell Carcinoma

Journal article

Open access

Peer reviewed

Patient Characteristics and Survival Outcomes of Non-Metastatic, Non-Clear Cell Renal Cell Carcinoma

Josiah An, Vignesh T. Packiam, Adithya Chennamadhavuni, Jordan Richards, Jayanshu Jain, Sarah L. Mott and Rohan Garje

Frontiers in oncology, Vol.11, pp.786307-786307

01/10/2022

DOI: 10.3389/fonc.2021.786307

PMCID: PMC8786111

PMID: 35083144

Files and links (1)

url

https://doi.org/10.3389/fonc.2021.786307View

Published (Version of record) Open Access

Abstract

BackgroundNon-clear cell renal cell carcinoma (ccRCC) includes histologically and molecularly distinct subtypes such as papillary, chromophobe, collecting duct, and sarcomatoid RCC, with an incidence ranging from 20% to 25%. Oncologic outcomes and the role of adjuvant systemic therapy [vascular endothelial growth factor inhibitor (VEGFi) or immunotherapy] for non-ccRCC are not well-described. ObjectiveTo assess the incidence and survival outcomes of non-ccRCC subtypes in comparison to ccRCC. MethodsThe National Cancer Database was utilized to identify patients with non-metastatic RCC (T1-T4, N0-N1) between 2004 and 2015. The non-ccRCC cohort was further stratified by histologic subtype: papillary, chromophobe, sarcomatoid, and collecting duct RCC. Multivariable Cox regression models were used to compare overall survival (OS). ResultsThe 5-year OS for chromophobe, papillary, clear cell, collecting duct, and sarcomatoid RCC was 91%, 82%, 81%, 44%, and 40%, respectively. After adjusting for clinicopathologic and treatment characteristics, there was no significant difference in OS between papillary RCC and ccRCC (p = 0.17). Patients with collecting duct and sarcomatoid subtypes were at over two times increased risk of death compared to patients with clear cell (p < 0.01 and p < 0.01, respectively). Conversely, patients with chromophobe RCC were at 36% decreased risk of death compared to ccRCC (p < 0.01). ConclusionsThis hospital-based analysis confirms that collecting duct and sarcomatoid histologic subtypes are uncommon and associated with poor survival after surgery when compared to the other RCC subtypes. Further studies are needed to evaluate the role of neoadjuvant and adjuvant systemic therapies in these subtypes to improve oncologic outcomes.

Life Sciences & Biomedicine

Oncology

Science & Technology

Details

Title: Subtitle: Patient Characteristics and Survival Outcomes of Non-Metastatic, Non-Clear Cell Renal Cell Carcinoma
Creators: Josiah An - University of Iowa Hospitals and Clinics
Vignesh T. Packiam - University of Iowa
Adithya Chennamadhavuni - University of Iowa Hospitals and Clinics
Jordan Richards - University of Iowa
Jayanshu Jain - University of Iowa Hospitals and Clinics
Sarah L. Mott - University of Iowa
Rohan Garje - University of Iowa Hospitals and Clinics
Resource Type: Journal article
Publication Details: Frontiers in oncology, Vol.11, pp.786307-786307
DOI: 10.3389/fonc.2021.786307
PMID: 35083144
PMCID: PMC8786111
NLM abbreviation: Front Oncol
ISSN: 2234-943X
eISSN: 2234-943X
Publisher: Frontiers Media Sa
Number of pages: 8
Language: English
Date published: 01/10/2022
Academic Unit: Hematology, Oncology, and Blood & Marrow Transplantation; Urology; Internal Medicine
Record Identifier: 9984320069802771

Metrics

14 Record Views

8 Times Cited - Web of Science

See more details